Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Leukemia, Myeloid, Acute 36Advanced Solid Tumors 20Myelodysplastic Syndromes 14Carcinoma, Non-Small-Cell Lung 14Breast Neoplasms 13Advanced Solid Tumor 13Recurrence 10Ovarian Neoplasms 8Neoplasms 8Multiple Myeloma 8Leukemia, Myelomonocytic, Chronic 8Triple Negative Breast Neoplasms 7Solid Tumor 6Myeloproliferative Disorders 6Small Cell Lung Carcinoma 5Prostatic Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasm Metastasis 5Lymphoma, Large B-Cell, Diffuse 5Lung Neoplasms 5Carcinoma, Hepatocellular 5Advanced Solid Tumour 5Sarcoma 4Melanoma 4Lymphoma, B-Cell 4Fallopian Tube Neoplasms 4Colorectal Neoplasms 4Advanced Malignant Solid Tumor 4Advanced Lung Cancer 4Squamous Cell Carcinoma of Head and Neck 3

Interventions

toripalimab 1Premedication 1Injections 1Immune Checkpoint Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Malignant Solid Tumors × Injections × 1 year × Clear all
NCT07480733 2026-05-29

Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors

Shanghai Junshi Bioscience Co., Ltd.

Phase 2 Recruiting
410 enrolled
Other solid neoplasm

Advanced Malignant Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡